EP2207669A4 - Compositions bactériostatiques ou bactériocides et procédés - Google Patents

Compositions bactériostatiques ou bactériocides et procédés

Info

Publication number
EP2207669A4
EP2207669A4 EP08842668A EP08842668A EP2207669A4 EP 2207669 A4 EP2207669 A4 EP 2207669A4 EP 08842668 A EP08842668 A EP 08842668A EP 08842668 A EP08842668 A EP 08842668A EP 2207669 A4 EP2207669 A4 EP 2207669A4
Authority
EP
European Patent Office
Prior art keywords
bacteriostatic
methods
bacteriocidal compositions
bacteriocidal
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08842668A
Other languages
German (de)
English (en)
Other versions
EP2207669A1 (fr
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/fr
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/fr
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/fr
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2207669A1 publication Critical patent/EP2207669A1/fr
Publication of EP2207669A4 publication Critical patent/EP2207669A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP08842668A 2007-10-25 2008-10-23 Compositions bactériostatiques ou bactériocides et procédés Withdrawn EP2207669A4 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US98272007P 2007-10-25 2007-10-25
US98271907P 2007-10-25 2007-10-25
PCT/US2007/082578 WO2008052143A2 (fr) 2006-10-25 2007-10-25 Dispositif de mélange et ses fluides de sortie
PCT/US2007/082581 WO2008115290A2 (fr) 2006-10-25 2007-10-25 Méthodes de soins et de traitement de plaies
PCT/US2007/082580 WO2008052145A2 (fr) 2006-10-25 2007-10-25 Procédés de traitement thérapeutique des yeux et d'autres tissus humains à l'aide d'une solution enrichie en oxygène
US4841608P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
US4834008P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
PCT/US2008/081029 WO2009055620A1 (fr) 2007-10-25 2008-10-23 Compositions bactériostatiques ou bactériocides et procédés

Publications (2)

Publication Number Publication Date
EP2207669A1 EP2207669A1 (fr) 2010-07-21
EP2207669A4 true EP2207669A4 (fr) 2011-11-02

Family

ID=42238385

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08842668A Withdrawn EP2207669A4 (fr) 2007-10-25 2008-10-23 Compositions bactériostatiques ou bactériocides et procédés
EP08841984.1A Not-in-force EP2214712B1 (fr) 2007-10-25 2008-10-27 Compositions et procédés de traitement d'asthme et de troubles pulmonaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08841984.1A Not-in-force EP2214712B1 (fr) 2007-10-25 2008-10-27 Compositions et procédés de traitement d'asthme et de troubles pulmonaires

Country Status (8)

Country Link
EP (2) EP2207669A4 (fr)
JP (3) JP5586470B2 (fr)
CN (3) CN101909869B (fr)
AU (2) AU2008316708A1 (fr)
CA (2) CA2703648A1 (fr)
IL (2) IL205321A0 (fr)
MX (1) MX2010004549A (fr)
WO (1) WO2009055620A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
WO2008052143A2 (fr) 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie
EP2097107B1 (fr) 2006-10-25 2016-05-04 Revalesio Corporation Traitement thérapeutique des yeux à l'aide d'une solution enrichie en oxygène
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
CN101909869B (zh) * 2007-10-25 2014-12-17 利发利希奥公司 抑菌或杀菌的组合物和方法
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
MX2010004563A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.
CA2723215A1 (fr) 2008-05-01 2009-11-05 Revalesio Corporation Compositions et methodes de traitement de troubles digestifs
PL2391419T3 (pl) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP2566460A4 (fr) 2010-05-07 2015-12-23 Revalesio Corp Compositions et procédés d'amélioration des performances physiologiques et du temps de récupération
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
WO2012019136A2 (fr) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Appareil d'injection et procédé d'administration de médicament
WO2012019139A1 (fr) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Procédés et appareils d'administration combinée de médicament
CA2808189A1 (fr) 2010-08-12 2012-02-16 Revalesio Corporation Compositions et methodes pour traiter une tauopathie
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
RS61758B1 (sr) 2011-09-16 2021-05-31 Forsight Vision4 Inc Aparati za razmenu tečnosti
WO2013116061A1 (fr) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Procédés et instrument pour l'insertion et le retrait de dispositifs thérapeutiques
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
CA2905496A1 (fr) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systemes pour l'administration intra-oculaire entretenue de composes a faible solubilite provenant d'un implant de systeme de pose d'orifice
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
KR101930573B1 (ko) * 2014-04-23 2018-12-18 주식회사 티씨엠생명과학 세포 도말 장치 및 세포 도말 방법
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
CN107106551A (zh) 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法
RU2708958C2 (ru) 2014-11-10 2019-12-12 Форсайт Вижн4, Инк. Расширяемые устройства доставки лекарственных средств и способы использования
MX2018006234A (es) 2015-11-20 2018-08-14 Forsight Vision4 Inc Estructuras porosas para dispositivos de suministro de medicamentos de liberacion prolongada.
MX2018012021A (es) 2016-04-05 2019-01-24 Forsight Vision4 Inc Dispositivos de administracion de farmacos oculares implantables.
CN114098949B (zh) * 2016-06-27 2023-12-19 盖能适治疗股份有限公司 发生器和具有电极的导管
WO2019103906A1 (fr) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Appareil d'échange de fluide pour système d'administration à port extensible et méthodes d'utilisation
US11759677B2 (en) 2018-02-16 2023-09-19 University Of Louisville Research Foundation, Inc. Respiratory training and airway pressure monitoring device
KR102171489B1 (ko) * 2018-10-30 2020-10-29 (주)메가메디칼 네블라이저 및 산소공급기가 구비되는 네블라이저 장치
US20230210848A1 (en) * 2020-04-30 2023-07-06 Fujifilm Toyama Chemical Co., Ltd. Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083610A1 (en) * 2001-02-01 2003-05-01 Mcgrath Terrence S. Compositions and method of tissue superoxygenation
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
WO2005113026A2 (fr) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Procede de traitement des troubles respiratoires et de l'inflammation des voies respiratoires
WO2006133113A2 (fr) * 2005-06-03 2006-12-14 BAGLEY David Systeme pour la fabrication et le conditionnement d'eau suroxygenee et structuree
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie
WO2009055729A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour traiter une inflammation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157720A (ja) * 1996-11-07 1999-03-02 Honda Motor Co Ltd 電解機能水、その製造方法及び製造装置
IL124788A (en) * 1998-06-07 1999-04-11 Ben Hador David Boomerang launcher
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
WO2001030754A2 (fr) * 1999-10-26 2001-05-03 Bio-Hydration Research Lab, Inc. Liquides micro-agreges et leurs procedes de fabrication et d'utilisation
US6426066B1 (en) * 2000-01-12 2002-07-30 California Pacific Labs, Inc. Use of physiologically balanced, ionized, acidic solution in wound healing
KR100521735B1 (ko) * 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
US20030199089A1 (en) * 2001-06-05 2003-10-23 Surber Mark W. Membrane to membrane delivery
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE602004031667D1 (de) * 2003-11-10 2011-04-14 Merck & Co Inc Substituierte trialzole als blocker des natriumkanals
JP4144669B2 (ja) * 2004-03-05 2008-09-03 独立行政法人産業技術総合研究所 ナノバブルの製造方法
CA2574848A1 (fr) * 2004-08-05 2006-12-21 Wyeth Inhibition de l'activite du recepteur d'interleukine 21
WO2008018932A2 (fr) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Procédé et utilisation de dispositifs à échelle nanométrique pour la réduction d'une lésion tissulaire lors d'un incident ischémique ou de reperfusion
EP2083876A4 (fr) * 2006-10-25 2012-09-19 Revalesio Corp Méthodes de soins et de traitement de plaies
CN101909869B (zh) * 2007-10-25 2014-12-17 利发利希奥公司 抑菌或杀菌的组合物和方法
MX2010004563A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.
JP2011050844A (ja) * 2009-09-01 2011-03-17 Kurita Water Ind Ltd 電気浸透脱水方法及び装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
US20030083610A1 (en) * 2001-02-01 2003-05-01 Mcgrath Terrence S. Compositions and method of tissue superoxygenation
WO2005113026A2 (fr) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Procede de traitement des troubles respiratoires et de l'inflammation des voies respiratoires
WO2006133113A2 (fr) * 2005-06-03 2006-12-14 BAGLEY David Systeme pour la fabrication et le conditionnement d'eau suroxygenee et structuree
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie
WO2009055729A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour traiter une inflammation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KHUSHBU K. MODI ET AL: "A Physically-Modified Saline Suppresses Neuronal Apoptosis, Attenuates Tau Phosphorylation and Protects Memory in an Animal Model of Alzheimer's Disease", PLOS ONE, vol. 9, no. 8, 4 August 2014 (2014-08-04), pages e103606, XP055163418, DOI: 10.1371/journal.pone.0103606 *
S. KHASNAVIS ET AL: "Suppression of Nuclear Factor- B Activation and Inflammation in Microglia by Physically Modified Saline", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 35, 24 August 2012 (2012-08-24), pages 29529 - 29542, XP055062907, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.338012 *
SAURABH KHASNAVIS ET AL: "Protection of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease by a Physically-Modified Saline Containing Charge-Stabilized Nanobubbles", JOURNAL OF NEUROIMMUNE PHARMACOLOGY, vol. 9, no. 2, 11 October 2013 (2013-10-11), pages 218 - 232, XP055164426, ISSN: 1557-1890, DOI: 10.1007/s11481-013-9503-3 *
See also references of WO2009055620A1 *

Also Published As

Publication number Publication date
CN101909649A (zh) 2010-12-08
AU2008316708A1 (en) 2009-04-30
EP2214712A4 (fr) 2013-02-27
WO2009055620A1 (fr) 2009-04-30
EP2214712B1 (fr) 2016-05-18
IL205320A (en) 2017-03-30
CA2703714A1 (fr) 2009-04-30
CN101909869B (zh) 2014-12-17
JP2011500854A (ja) 2011-01-06
IL205321A0 (en) 2010-12-30
AU2008316556A1 (en) 2009-04-30
CN101909869A (zh) 2010-12-08
MX2010004549A (es) 2010-07-28
JP2015028087A (ja) 2015-02-12
CN103721258B (zh) 2015-12-09
AU2008316556B2 (en) 2014-12-18
CN101909649B (zh) 2014-01-29
CN103721258A (zh) 2014-04-16
JP5586470B2 (ja) 2014-09-10
EP2214712A1 (fr) 2010-08-11
JP2011500838A (ja) 2011-01-06
EP2207669A1 (fr) 2010-07-21
CA2703648A1 (fr) 2009-04-30
IL205320A0 (en) 2010-12-30
JP5750540B2 (ja) 2015-07-22
JP5647897B2 (ja) 2015-01-07

Similar Documents

Publication Publication Date Title
EP2207669A4 (fr) Compositions bactériostatiques ou bactériocides et procédés
HUS2300039I1 (hu) PSMA-kötõ szerek és alkalmazásaik
EP2162004A4 (fr) Compositions antimicrobiennes et leurs utilisations
HK1183435A1 (en) Frizzled-binding agents and uses thereof
ZA201001300B (en) Antigen-asjuvant compositions and methods
HK1158495A1 (en) Hair conditioner composition
EP2219554A4 (fr) Dispositifs et compositions contenant de la progestérone
EP2276339A4 (fr) Composition antimicrobienne et utilisation
IL211204A0 (en) Mucoadherents compositions and their use
GB0721291D0 (en) Methods and compositions
GB0622399D0 (en) Novel compositions and uses thereof
GB0813323D0 (en) Antimicrobial compositions and methods
GB0717376D0 (en) Composition and manufacture thereof
GB0809912D0 (en) Novel compositions and uses thereof
GB0719526D0 (en) Compositions and methods
EP1998753A4 (fr) Compositions pour depot important et leurs utilisations
EP2247303A4 (fr) Compositions modulant l'hémostase et utilisations associées
GB0715428D0 (en) Compositions and uses thereof
GB0701170D0 (en) Compositions and uses thereof
GB0624132D0 (en) Hair conditioning compositions
GB0622400D0 (en) Novel compositions and uses thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0701171D0 (en) Compositions and uses thereof
EP2010141A4 (fr) Compositions à fort dépôt et leurs utilisations
GB0725264D0 (en) Compositions and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111006

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20110929BHEP

Ipc: C12N 13/00 20060101ALI20110929BHEP

Ipc: A61K 33/00 20060101ALI20110929BHEP

Ipc: C12N 5/00 20060101AFI20110929BHEP

17Q First examination report despatched

Effective date: 20130527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160927